The effect of Chaihu-Huaji decoction on postoperative syndrome of TACE and the influence of inflammatory factors on primary liver cancer
- Conditions
- Primary liver cancer
- Registration Number
- ITMCTR2100004993
- Lead Sponsor
- Chongqing Traditional Chinese Medicine Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Those who meet the above-mentioned Western medicine diagnostic criteria for primary liver cancer and TCM syndrome differentiation;
2. Patients with CNLC stage Ib-IIIa;
3. Have not received any treatment for HCC, such as surgical resection, ablation, TACE, etc.;
4. Those who have good compliance, take medicine on time, review at the specified time, and have a cheerful personality;
5. Patients between the ages of 18 and 70;
6. The choice of embolic agent is ultra-liquefied lipiodol, and the dosage is determined according to the size of the tumor. The maximum amount of one administration does not exceed 20ml.
1. Combined with other systemic malignant tumors at the same time;
2. Serious adverse drug reactions;
3. Combined with severe complications of advanced decompensation of tumor and liver cirrhosis, such as upper gastrointestinal bleeding, hepatorenal syndrome, hepatic encephalopathy, etc.;
4. Those who are mentally ill or unable to cooperate;
5. There are absolute contraindications to TACE treatment;
6. Patients with severe heart disease, or kidney, brain, lung and hematopoietic system diseases;
7. The researcher believes that it is not suitable to participate in this clinical researcher.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method